U.S. Markets closed
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • Dow 30

    29,910.37
    +37.90 (+0.13%)
     
  • Nasdaq

    12,205.85
    +111.44 (+0.92%)
     
  • Russell 2000

    1,855.27
    +10.25 (+0.56%)
     
  • Crude Oil

    45.53
    -0.18 (-0.39%)
     
  • Gold

    1,788.10
    -23.10 (-1.28%)
     
  • Silver

    22.55
    -0.81 (-3.46%)
     
  • EUR/USD

    1.1965
    +0.0051 (+0.4307%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • Vix

    20.84
    -0.41 (-1.93%)
     
  • GBP/USD

    1.3303
    -0.0054 (-0.4031%)
     
  • USD/JPY

    104.0530
    -0.1970 (-0.1890%)
     
  • BTC-USD

    17,059.10
    +334.30 (+2.00%)
     
  • CMC Crypto 200

    334.04
    -3.46 (-1.03%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

Omeros: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of Omeros (NASDAQ:OMER) were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 30.30% year over year to ($0.43), which beat the estimate of ($0.61).

Revenue of $26,114,000 declined by 12.53% year over year, which beat the estimate of $19,110,000.

Guidance

Omeros hasn't issued any earnings guidance for the time being.

Omeros hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 09, 2020

View more earnings on OMER

Time: 04:30 PM

ET Webcast URL: https://investor.omeros.com/upcoming-events

Recent Stock Performance

52-week high: $25.46

Company's 52-week low was at $8.50

Price action over last quarter: down 30.84%

Company Description

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.